LH vs NEO
LH: Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry. NEO: NeoGenomics is a leading provider of oncology diagnostic solutions that empower clinicians and patients with actionable insights to guide personalized cancer care.
Side-by-side fundamentals
| Metric | LH | NEO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $314.20 | $16.02 | |
| Market cap | $25.5B | $2.1B | |
| P/E as of 2026-10-08 | 25.98 | n/a | |
| Net margin FY2025, SEC XBRL | +6.3% | n/a | |
| Gross margin FY2025, SEC XBRL | +28.8% | n/a | |
| Operating margin FY2025, SEC XBRL | +9.9% | n/a | |
| ROE FY2025, SEC XBRL | +10.2% | -12.9% | LH higher |
| ROA FY2025, SEC XBRL | +4.8% | -7.9% | LH higher |
| Debt / equity as of 2026-09-03 | 0.69 | 0.48 | NEO lower |
| Revenue growth (YoY) as of 2026-09-03 | +6.4% | +11.2% | NEO higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-09-03 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-09-03 | 0.54 | 1.18 | |
| 1-year return as of 2026-10-08 close | +13.2% | +74.7% | NEO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.